{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:44:44Z","timestamp":1773413084132,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clgc.2022.07.003","type":"journal-article","created":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T18:00:50Z","timestamp":1657476050000},"page":"488-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study"],"prefix":"10.1016","volume":"20","author":[{"given":"Elie","family":"Rassy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Dalban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emeline","family":"Colomba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Derosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Alves Costa Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Negrier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Chevreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwenaelle","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Laguerre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Barthelemy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine Gross","family":"Goupil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionnel","family":"Geoffrois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Thiery-Vuillemin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Ladoire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Tantot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.07.003_bib0001","unstructured":"Cancer today [Internet]. [cited 2021 Jan 23]. Available at: http:\/\/gco.iarc.fr\/today\/home."},{"key":"10.1016\/j.clgc.2022.07.003_bib0002","unstructured":"Kidney and Renal Pelvis Cancer \u2014 Cancer Stat Facts [Internet]. [cited 2021 Jan 23]. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html."},{"issue":"4","key":"10.1016\/j.clgc.2022.07.003_bib0003","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.07.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920907504","article-title":"Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma","volume":"12","author":"Rassy","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2022.07.003_bib0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2019.06.022","article-title":"Sequencing and combination of systemic therapy in metastatic renal cell carcinoma","volume":"2","author":"de Velasco","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2022.07.003_bib0006","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.eururo.2017.02.010","article-title":"CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.clgc.2022.07.003_bib0007","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clgc.2022.07.003_bib0008","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clgc.2022.07.003_bib0009","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2022.07.003_bib0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1634\/theoncologist.2016-0476","article-title":"FDA approval summary: nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis","volume":"22","author":"Xu","year":"2017","journal-title":"Oncologist"},{"issue":"19","key":"10.1016\/j.clgc.2022.07.003_bib0011","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"6371","key":"10.1016\/j.clgc.2022.07.003_bib0012","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.clgc.2022.07.003_bib0013","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.clgc.2022.07.003_bib0014","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1080\/19490976.2018.1527167","article-title":"The intimate relationship between gut microbiota and cancer immunotherapy","volume":"10","author":"Elkrief","year":"2019","journal-title":"Gut Microbes"},{"issue":"2","key":"10.1016\/j.clgc.2022.07.003_bib0015","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eururo.2020.04.044","article-title":"Gut bacteria composition drives primary resistance to cancer immunotherapy in renal cell carcinoma patients","volume":"78","author":"Derosa","year":"2020","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2022.07.003_bib0016","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdy103","article-title":"Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer","volume":"29","author":"Derosa","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2022.07.003_bib0017","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1136\/gutjnl-2015-310376","article-title":"Proton pump inhibitors affect the gut microbiome","volume":"65","author":"Imhann","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.clgc.2022.07.003_bib0018","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2017.03.001","article-title":"Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation","volume":"43","author":"Huber","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clgc.2022.07.003_bib0019","first-page":"203","article-title":"Medication use and kidney cancer risk: a population-based study","volume":"83","author":"Nayan","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"6","key":"10.1016\/j.clgc.2022.07.003_bib0020","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.clgc.2017.05.019","article-title":"Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"15","author":"Lalani","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2022.07.003_bib0021","article-title":"Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma","volume":"11","author":"Mollica","year":"2021","journal-title":"Target Oncol"},{"issue":"23","key":"10.1016\/j.clgc.2022.07.003_bib0022","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.18.02218","article-title":"Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase ii study","volume":"37","author":"Flippot","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2022.07.003_bib0023","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1038\/s41467-018-05184-7","article-title":"Gut microbiota associations with common diseases and prescription medications in a population-based cohort","volume":"9","author":"Jackson","year":"2018","journal-title":"Nat Commun"},{"issue":"7698","key":"10.1016\/j.clgc.2022.07.003_bib0024","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nature25979","article-title":"Extensive impact of non-antibiotic drugs on human gut bacteria","volume":"555","author":"Maier","year":"2018","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.clgc.2022.07.003_bib0025","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/apt.14451","article-title":"Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications","volume":"47","author":"Le Bastard","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clgc.2022.07.003_bib0026","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev-pharmtox-010510-100510","article-title":"Mechanisms of monoclonal antibody-drug interactions","volume":"51","author":"Zhou","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.clgc.2022.07.003_bib0027","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ddtec.2016.09.004","article-title":"Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies","volume":"21-22","author":"Kamath","year":"2016","journal-title":"Drug Discov Today Technol"},{"key":"10.1016\/j.clgc.2022.07.003_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106972","article-title":"The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy","volume":"88","author":"Li","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clgc.2022.07.003_bib0029","doi-asserted-by":"crossref","first-page":"vi115","DOI":"10.1093\/annonc\/mdz338.107","article-title":"MO3-10-1 - The effect of proton pump inhibitors on the efficacy of nivolumab monotherapy in different types of cancer","volume":"30","author":"Nguyen","year":"2019","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2022.07.003_bib0030","doi-asserted-by":"crossref","first-page":"e14092","DOI":"10.1200\/JCO.2019.37.15_suppl.e14092","article-title":"Proton pump inhibitors and response to immune check-point inhibitors: single center study","volume":"37","author":"Trabolsi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2022.07.003_bib0031","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s12094-019-02282-w","article-title":"Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer","volume":"22","author":"Iglesias-Santamar\u00eda","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2022.07.003_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2022.07.003_bib0033","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/CMR.0000000000000299","article-title":"Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma","volume":"26","author":"Failing","year":"2016","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.clgc.2022.07.003_bib0034","first-page":"762","article-title":"Do proton pump inhibitors modulate the efficacy of anti-PD-1\/PD-L1 therapy? A retrospective study","volume":"25","author":"Mukherjee","year":"2019","journal-title":"J Oncol"},{"issue":"10","key":"10.1016\/j.clgc.2022.07.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2022.07.003_bib0036","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.21873\/anticanres.14182","article-title":"Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer","volume":"40","author":"Svaton","year":"2020","journal-title":"Anticancer Res"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2022.07.003_bib0037","doi-asserted-by":"crossref","first-page":"e21040","DOI":"10.1200\/JCO.2019.37.15_suppl.e21040","article-title":"What impact do the proton pump inhibitors have on the efficacy of immune check point inhibitors in metastatic malignant melanoma?","volume":"37","author":"Afzal","year":"2019","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.clgc.2022.07.003_bib0038","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-20-1876","article-title":"Concomitant proton pump inhibitor use and survival in urothelial carcinoma treated with atezolizumab","volume":"26","author":"Hopkins","year":"2020","journal-title":"Clin Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2022.07.003_bib0039","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","article-title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials","volume":"31","author":"Chalabi","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.07.003_bib0040","doi-asserted-by":"crossref","first-page":"x40","DOI":"10.1093\/annonc\/mdy511.001","article-title":"Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients","volume":"29","author":"Homicsko","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:36:02Z","timestamp":1761564962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322001550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1558767322001550"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.07.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}